FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopa... ( EVISTA does not increase or decrease ...)

HOME >> MEDICINE >> TECHNOLOGY

FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women

Date:9/14/2007

EVISTA does not increase or decrease the incidence of heart attack, stroke, cardiovascular death, or overall death. In a study of postmenopausal women at high risk for cardiovascular disease taking EVISTA, there was no increase in the incidence of stroke; however, there was an increase in the incidence of death due to stroke. If you have had a stroke or have a history of other significant risk factors for stroke, such as a mini-stroke (TIA/transient ischemic attack), hypertension, history of cigarette smoking or a type of irregular heartbeat (atrial fibrillation), you should discuss with your healthcare professional the risks versus benefits of taking EVISTA.

If you have kidney or liver problems, you should discuss these conditions with your healthcare professional before taking EVISTA.

The most commonly reported side effects are hot flashes, leg cramps, peripheral edema, arthralgia, flu syndrome and sweating. Side effects with EVISTA are usually mild, and most women don't find them serious enough to stop taking it.

Important Limitations of Use for Breast Cancer Risk Reduction

EVISTA is indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer. The American Cancer Society estimates that approximately 180,000 women are diagnosed with invasive breast cancer each year(3).

EVISTA does not treat existing breast cancer, reduce the risk of getting breast cancer again or reduce the risk of all forms of breast cancer. For more information about EVISTA including prescribing information and boxed warning, log on to http://www.evista.com

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations wi
'/>"/>

5

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. FDA approves IND on Lead Product M6G
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
5. Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
11. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Post Your Comments:

FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopa...( EVISTA does not increase or decrease ...),Health